Patents by Inventor Mark Sleeman

Mark Sleeman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120128679
    Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
    Type: Application
    Filed: November 22, 2011
    Publication date: May 24, 2012
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
  • Publication number: 20060058224
    Abstract: Compositions and methods of treating obesity or obesity-related condition, including reducing body-weight, improving-diabetic parameters, metabolic syndrome. liver steatosis, and/or hypertension with a combination of CNTF or a CNTF-related molecule and a second agent which is a therapeutic molecule useful in the treatment of obesity, type II diabetes, or other obesity-related conditions.
    Type: Application
    Filed: September 15, 2005
    Publication date: March 16, 2006
    Inventors: George Yancopoulos, Stanley Wiegand, Mark Sleeman, Ellen-Marie Koehler-Stec
  • Publication number: 20060024309
    Abstract: Methods of treating diabetes in mammals, particularly humans, by blocking or inhibiting VEGF-mediated activity. A preferred inhibitor of VEGF-mediated activity is a VEGF antagonist such as the VEGF fusion protein trap of SEQ ID NO:2 capable of binding and blocking VEGF. The method of the invention may be combined with other therapies, such as with insulin therapy.
    Type: Application
    Filed: July 29, 2005
    Publication date: February 2, 2006
    Inventors: Jingtai Cao, Li-Hsien Wang, Hsin Lin, Mark Sleeman, Stanley Wiegand
  • Publication number: 20050250185
    Abstract: A fusion polypeptide comprising an orphan glyprotein hormone (OGH), OGH-family member, or a fragment thereof; a glycoprotein hormone subunit ?1 or ?2, or a fragment thereof, and optionally a peptide (P), and a fusion component (F). In one embodiment, the fusion protein comprises hOGH-hFc-h?2 or hTSH-hFc-h?1.
    Type: Application
    Filed: December 9, 2004
    Publication date: November 10, 2005
    Inventors: Andrew Murphy, Lynn Macdonald, Mark Sleeman
  • Publication number: 20050096264
    Abstract: A method of treating or ameliorating an orphan glycoprotein hormone (OGH)-related condition or a condition which responds to OGH administration, comprising administering an OGH-related compound to a subject in need thereof.
    Type: Application
    Filed: November 16, 2004
    Publication date: May 5, 2005
    Inventors: Lynn MacDonald, Mark Sleeman, Andrew Murphy
  • Publication number: 20050070519
    Abstract: A process for the preparation of a substituted C-2 ?-lactam comprises incubating a 2-substituted 3-aminocarboxylic acid with a ?-lactam synthetase under conditions such that the 2-substituted 3-aminocarboxylic acid is cyclised to produce a substituted C-2 ?-lactam. The process can be used to produce an antibiotic or ?-lactamase inhibitor.
    Type: Application
    Filed: December 19, 2002
    Publication date: March 31, 2005
    Inventors: Christopher Schofield, Kirsty Hewitson, Mark Sleeman